Investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with The Medicine Company’s antithrombotic agent, Kengreal (cangrelor) for injection at the 65th Annual Scientific Session of the American College of Cardiology, held April 2-4, in Chicago, USA.
CHAMPION PHOENIX included 11,145 patients comparing cangrelor to oral clopidogrel in patients undergoing PCI and provided the primary evidence of efficacy for the approval of cangrelor.
The results from the dedicated CHAMPION PHOENIX ECONOMICS sub-study on the cost implications of procedural thrombotic complications in patients undergoing PCI will also be presented during the meeting.
Efthymios N. Deliargyris, global medical director, Acute Cardiovascular Care for The Medicines Company, says, “The new analyses presented at this meeting further enhance our understanding of how the clinical efficacy and value of cangrelor can potentially improve clinical outcomes and streamline efficiency in certain PCI patients.”
The company is also sponsoring a symposium at the meeting, which will be moderated by C Michael Gibson, chief of Clinical Research in the Cardiovascular Division at Beth Israel Deaconess Medical Center, Harvard Medical School, (Boston, USA).
